Diabetes Care 44(11):25892625
This review examines the link between diabetes and neurodegenerative diseases, explores the effects of antidiabetic agents on neurodegeneration, provides a concise overview of the GLP-1 pathway, and discusses both preclinical and clinical trial outcomes of GLP-1RAs for neurodegenerative diseases, including their effects on cognition in AD and PD
Unfortunately, its a common occurrence, Magge said, adding that shes rarely able to get weight loss medications covered for her patients.Nationwide shortages of the medications compound the problem, she said
Friedrichsen, M., Breitschaft, A., Tadayon, S., Wizert, A
Not for use by individuals under the age of 18 years